A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
R-Pharm International, LLC · Metastatic Castration-resistant Prostate Cancer
Phase 2
Active, not recruiting
120
2026-04
Industry sponsor intelligence
R-Pharm International, LLCClinical Pipeline.
Lead-sponsor view of R-Pharm International, LLC's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 120
Pipeline overview
Programs by phase and activity.
Velocity
R-Pharm International, LLC trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Goserelin → | 1 | 0 | 1 | 0 | 0 | 1 |
| Leuprolide → | 1 | 0 | 1 | 0 | 0 | 1 |
| Triptorelin → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All R-Pharm International, LLC studies.
This page groups studies where R-Pharm International, LLC is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates